Teneligliptin hydrobromide hydrate

Cat. No.:	HY-14806B
CAS No.:	1572583-29-9
Molecular Formula:	$C_{22}H_{30}N_6OS$
Molecular Weight:	426.58
Target:	Dipeptidyl Peptidase
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : ≥ 100 mg/mL (234.42 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.3442 mL	11.7211 mL	23.4423 mL
5 mM	0.4688 mL	2.3442 mL	4.6885 mL
10 mM	0.2344 mL	1.1721 mL	2.3442 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Teneligliptin hydrobromide hydrate is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC_{50}s of approximately 1 nM[1].

IC_{50} & Target

DPP-4

CUSTOMER VALIDATION

- Antioxidants (Basel). 2023 Jul 24;12(7):1478.
- Antioxidants (Basel). 2021 Sep 9;10(9):1438.
- Eur J Med Chem. 2021 Feb 15;212:113030.
- Nephrol Dial Transplant. 2019 Oct 1;34(10):1669-1680.
- Chem Res Toxicol. 2020 Aug 17;33(8):2164-2171.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA